The capacity to optimally treat cancer patients is nowadays challenged by several factors. These challenges are particularly caused by tumor heterogeneity and plasticity, causing tumor characteristics to change over time and under treatment pressure. The use of liquid biopsies sampled from the blood of patients with cancer is a promising way to evaluate tumor characteristics and response to therapy repeatedly during therapy. In the long run, the availability of these sort of biomarkers which can tailor the right therapeutic strategy, for the right person, at the right time, is where we can use knowledge on the biology of cancer to treat cancer in the most optimal fashion.

This thesis has focused on several technical and clinical aspects of liquid biopsies, all with the ultimate aim to allow personalized medicine based on these liquid biopsies.

Additional Metadata
Keywords Liquid biopsies, oncology, circulating tumor cells, cell-free DNA, circulating endothial cells, personalized medicine, breast cancer
Promotor S. Sleijfer (Stefan) , J.W.M. Martens (John)
Publisher Erasmus University Rotterdam
Sponsor Financial support for this thesis was generously provided by the Department of Medical Oncology of the Erasmus MC Cancer Institute, Erasmus University Rotterdam, Pfizer, AstraZeneca, Boehringer Ingelheim, Kyowa Kirin and Thermo Fisher Scientific.
ISBN 978-94-028-0449-2
Persistent URL
Note The work in this thesis was financially supported by Cancer Genomics Netherlands ( Organization for Scientific Research (NWO), the Dutch Cancer Society (KWF; grant numbers DDHK 2010-4678, EMCR 2012-5390, EMCR 2014-6340), Stichting Coolsingel (project #319), Janssen Diagnostics, Roche Netherlands and Pink Ribbon (project WO 61).
Beije, N. (2017, February). Personalized cancer medicine guided by liquid biopsies. Erasmus University Rotterdam. Retrieved from